NVO · Novo Nordisk A S

Track NVO — free

$43.09 -0.10 (-0.23%)

Rebalance outlook locked

Market Cap

$192.00B

4.42B

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 7 wks

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

+6.4%

Year over year

Operating margin

41.3%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

-27.1%

Trailing year

Short interest

0.7%

Latest settlement · 2.7 days to cover

View all 115 metrics

Equibles Research

our published analysis of this company

Research Thesis July 31, 2026

Novo Nordisk's 1.3 million Wegovy pill TRxs meet a 50% WAC cut — and the bear case still wins

Novo Nordisk is the only name in the GLP-1 bellwether set guiding negative adjusted-sales growth for 2026 (-4% to -12% at CER), even as Wegovy pill TRxs hit around 1.3 million in Q1 2026 and the 1 January 2027 WAC reset to USD 675 locks in further realised-price compression.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 15.4 · calm Equity put/call 0.52

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −6%

below

Price vs 50-day avg −8%

below

RSI (14) 41

neutral

MACD trend Negative

52-week position 28%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −7%

trailing

6-month return +19%

trailing

YTD return −15%

this year

Relative strength 0%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $47 › 200d $46 — 50d above 200d

Institutional flow Accumulating

+6% holders QoQ · +216 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.72% of float · ▼ -6.4% MoM · 2.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

1,368 holders — mid 3-yr range

Squeeze score 36

low risk · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 46%

annualized · 1-yr

Max drawdown −45%

past year

ATR 3.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Sep 30, 2025

Negative impact on full-year operating profit growth · 2026 3%

Prior guidance period ended · from the Earnings Call filed Jun 30, 2021

Operating profit growth · 2021 9% – 12%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−6% Bearish

Price vs 50-day avg

−8% Bearish

RSI (14)

41 Neutral

MACD trend

Negative Bearish

52-week position

28% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $47 › 200d $46 — 50d above 200d

Institutional flow Accumulating

+6% holders QoQ · +216 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.72% of float · ▼ -6.4% MoM · 2.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

1,368 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $35 Now $43 · 28% Range high $64

vs 200-day avg -6% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NVO Novo Nordisk A S this stock	$192.00B	-15.1%	—	—	0.7%
LLY ELI LILLY & Co	$1.07T	+7.2%	+44.7%	38.2	0.8%
JNJ Johnson & Johnson	$641.80B	+30.6%	+6.0%	30.9	0.9%
ABBV AbbVie Inc.	$464.82B	+15.5%	+8.6%	74.3	1.1%
MRK Merck & Co., Inc.	$357.37B	+39.8%	+1.3%	115.9	1.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

1,368

% held: 9.3%
Net QoQ: +3.9M sh
Top holder: Dodge & Cox

Held Float

View

Held by Funds

Fund positions

171

View

Short & Settlement

Short Interest Falling

Shares short

31.6M

Days to cover: 2.7d
Change: -2.2M sh

View

Short Volume

Short vol %

41%

As of: Sep 17, 2026

Short Total

View

Fails to Deliver

FTD shares

12.2K

Value: $594.6K
As of: Aug 26, 2026

View

Off-Exchange

Off-exchange %

47.5%

Week of: Aug 10, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Lisa McClain

Amount: $1.0K–$15.0K
Traded: Oct 31, 2025

View

Filings

SEC Filings

Latest

6-K

Filed: Sep 17, 2026
This year: 59

View

Proposed Sales

Value

$2.0M

Shares: 921.9K
Filed: May 30, 2025

View

Earnings & Events

Earnings Calls

Last call

Aug 5, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
NVO	-1.9%	-7.1%	+18.7%	-4.7%	-15.1%
SPY	+0.6%	-0.8%	+18.2%	-0.6%	+11.8%
vs SPY	-2.5%	-6.2%	+0.4%	-4.1%	-26.9%

Key facts CIK 353278 CUSIP 670100205 13F (30d) 32 filings 27 filers Visit website Investor relations

NVO · Novo Nordisk A S

Price & Indicators

Up next

Metrics snapshot

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance